CAS: 144412-49-7; (S)-2-((1-(2-(4-Carbamimidoylbenzamido)-3-(4-Hydroxyphenyl)Propanoyl)Piperidin-4-yl)Oxy)Acetic Acid

该化合物是一种合成化合物,被归类为对二/三甲基苯丙酸丙酮受体的非农药对抗者,在血盘组装中起着关键作用,主要被调查为有可能用于预防心血管疾病中的血栓事件.Lamifiban表现出对二/三甲基苯受体的高度亲和性,从而抑制了血盘聚合并减少凝血块形成的风险.该物质通常在临床环境中施用,通常与其他抗血压疗法结合使用.其药理学特征表明行动迅速开始,尽管具体细节可能因配方和病管途径而不同.Lamifiban的功效和安全特征已在各种临床试验中进行了评估,有助于了解其作为治疗剂的作用.与许多药剂一样,潜在的副作用可能包括出血并发症,这需要在治疗期间进行仔细监测.

结构式图片

合成工艺路线路线简述

  • 合成目标产物 Lamifiban 主要起始原料 Acetic Acid, 2-[[1-[(2S)-2-[[4-[(Hydroxyamino)Iminomethyl]Benzoyl]Amino]-3-(4-Hydroxyphenyl)-1-Oxopropyl]-4-Piperidinyl]Oxy]-
  • (文献来源)合成步骤主要原料 Acetic Acid, 2-[[1-[(2S)-2-[[4-[(Hydroxyamino)Iminomethyl]Benzoyl]Amino]-3-(4-Hydroxyphenyl)-1-Oxopropyl]-4-Piperidinyl]Oxy]-

海关参考信息

专利信息


专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人:BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

专利号:US-8143437-B2
优先权日:2002-02-19
标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
发明人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.

专利号:US-2005239725-A1
优先权日:2002-02-19
标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof

专利号:US-2005070715-A1
优先权日:2003-07-15
标 题:Methods for synthesis of acyloxyalkyl compounds

专利号:US-7560483-B2
优先权日:2002-02-19
标题 :Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002 Jan 22;105(3):316-21. Review. doi: 10.1007/s11239-013-0924-x. Review. doi: 10.2165/11595010-000000000-00000. Review.

合成参考文献


参考文献:10.1007/s003920050285
摘要:Klepzig H, Krobot K, Flettner R, Winten G, Zeiher AM. [Determinants of treatment costs of unstable angina pectoris]. Z Kardiol. 1999 Apr;88(4):261–9. doi: 10.1007/s003920050285.
参考文献:10.1007/s00018-002-8440-8
摘要:Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists - from bench to practice. Cellular and Molecular Life Sciences (CMLS). 2002 Mar 01;59(3):478–500. doi: 10.1007/s00018-002-8440-8.
参考文献:10.2165/00044011-199815050-00001
摘要:Gurfinkel E; Ushuaia Conference Group. Current treatment and future prospects for the management of acute coronary syndromes: consensus recommendations of the 1997 ushuaia conference, tierra del fuego, Argentina. Clin Drug Investig. 1998;15(5):367–80. doi: 10.2165/00044011-199815050-00001.
参考文献:10.1007/bf00735960
摘要:ten Cate H, Nurmohamed MT, ten Cate JW. Developments in antithrombotic therapy: state of the art anno 1996. International Journal of Clinical Pharmacy. 1996 Nov;18(6):195–203. doi: 10.1007/bf00735960.
参考文献:10.2165/00003495-199958040-00003
摘要:Kong DF, Califf RM. Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. Drugs. 1999 Oct;58(4):609–20. doi: 10.2165/00003495-199958040-00003.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知